Researchers from Yale Cancer Center identified the Cancer and Aging Research Group calculator as an effective tool in assessing chemotherapy toxicity probability in geriatric patients.
A pilot program developed by researchers at Yale Cancer Center offering next day access for oncologic consultation for patients showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report.
The phase III GEMSTONE-301 study demonstrated the efficacy and safety of the anti-PD-L1 antibody sugemalimab as consolidation therapy in patients with locally advanced/unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
Results from a phase III trial demonstrated the clinical benefit of using PD-1 inhibitor Libtayo (cemiplimab), in combination with a physician’s choice of platinum-doublet chemotherapy, in the treatment of patients with locally advanced or metastatic non-small cell lung cancer, irrespective of histology and across all PD-L1 expression levels.
UCLA Jonsson Comprehensive Cancer Center researchers found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly mitigates disease progression, compared to the current standard of care, trastuzumab emtansine (T-DM1).
Results from the phase III KEYNOTE-826 trial demonstrate that Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab improved disease outcomes when compared to chemotherapy with or without bevacizumab as a first-line treatment of persistent, recurrent, or metastatic cervical cancer.
The phase III IMpower010 trial reinforced the significant disease-free survival benefit offered by Tecentriq (atezolizumab) for people with stage II-IIIA non-small cell lung cancer whose tumors express PD-L1≥1%.
MIT researchers found that benzo(a)pyrene plays a small part—about 11%—in the global risk of developing polycyclic aromatic hydrocarbons (PAHs)-associated cancer.
A study published in the Journal of the National Comprehensive Cancer Network found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.
Updated results from CStone Pharmaceuticals’ phase III GEMSTONE-302 study indicate the effectiveness of the antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with stage IV non-small cell lung cancer.
